Clinical trials: Beta-lactam Antibiotics
- Condition Beta-lactam Antibiotics
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Bacterial Infections
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and extended spectrum class D…
- Trial name
- NCT04380207
- Testing
- QPX7728, QPX2014
- Where
- 2 sites in United States, Australia
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Bacterial Infections
Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects
QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum betalactamases (ESBLs), class C cephalosporinases, and extended spectrum class D…
- Trial name
- NCT05072444
- Testing
- QPX7728, QPX2014
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Bacterial Infections
Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects
QPX2015 (beta-lactam antibiotic) is being studied at higher than approved doses to combine with a new beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.
- Trial name
- NCT03939429
- Testing
- QPX2015
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.